BAMS
CHRS icon

Bellevue Asset Management (Switzerland)’s Coherus Oncology CHRS Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$5.9M Buy
257,000
+27,000
+12% +$695K 0.9% 37
2015
Q3 		$4.61M Sell
230,000
-20,000
-8% -$609K 0.75% 48
2015
Q2 		$7.22M Buy
250,000
+170,000
+213% +$4.3M 1% 31
2015
Q1 		$2.45M Buy
+80,000
New +$2.07M 0.34% 73

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s CHRS Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) increased its Coherus Oncology (CHRS) stake by 12% in Q4 2015, buying an estimated $695K and bringing the position to 257,000 shares worth $5.9M. The position accounts for 0.9% of the portfolio, ranked #37.

Bellevue Asset Management (Switzerland) first reported a position in CHRS in Q1 2015 and has held it in 4 quarters since. The position peaked at $7.22M in Q2 2015. 77 funds tracked by Wall St. Rank hold CHRS as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 257,000 shares of Coherus Oncology worth $5.9M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) bought 27,000 Coherus Oncology shares in Q4 2015, an estimated $695K.
  • Coherus Oncology made up 0.9% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #37 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Coherus Oncology in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Coherus Oncology position peaked at $7.22M in Q2 2015.
  • 77 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.